ClinicalTrials.gg

Program

Anti-CD19-Glucosteroid Receptor Modulator ADC ABBV-31

In AbbVie’s pipeline, CD19. Its studies are mostly in Lymphoma, Large B-Cell, Diffuse · Dry Eye Syndromes, led by AbbVie.

Furthest: phase 1, since Aug 22, 20222 company-led studies, 2 open or runningNext primary completion: Feb 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie22 open or runningphase 1since Aug 22, 2022Aug 22, 2022Feb 2027phase 1 · NCT05512390
  • Named in AbbVie’s own pipeline as ABBV-319, phase 1, as of Jul 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 22, 2022First study: phase 1 study in Lymphoma, Large B-Cell, DiffuseFirst studyNCT05512390 · 39 enrolled · United States, Australia, Canada and more
  2. May 12, 2025Phase 1 study in Dry Eye SyndromesNCT06977724 · 36 planned · United States, France, Netherlands

Ahead

  1. Feb 2027Primary completion: phase 1 study in Lymphoma, Large B-Cell, DiffuseNCT05512390
  2. Mar 2029Primary completion: phase 1 study in Dry Eye SyndromesNCT06977724

TargetBeta

“CD19”the company's pipeline, read by Claude · source
“An antibody drug conjugate (ADC) composed of an afucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against the B-cell-specific membrane protein CD19 ”NCIt, by rule

Other programs on CD19

ProgramCompanyFurthest phaseStudies
blinatumomabruleAmgenphase 429
inebilizumabruleAmgenphase 419
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012FAstraZenecaphase 312
axicabtagene ciloleucelruleGilead Sciencesphase 310
surovatamigAstraZenecaphase 310
lisocabtagene maraleucelruleBristol-Myers Squibbphase 310
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 38
obexelimabzenas-biopharma-usa-llcphase 37
Autologous Anti-CD19 CAR-T Cells CABA-201rulecabaletta-biophase 36
zolacabtagene autoleucelBristol-Myers Squibbphase 36
Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753ruleGilead Sciencesphase 32
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06977724Dry Eye Syndromes · United States, France, Netherlands1RecruitingMar 202936
NCT05512390Lymphoma, Large B-Cell, Diffuse · United States, Australia, Canada and more1Active, not recruitingFeb 202739

How it is read

Names in the registry

  • “ABBV-319”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.